Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Semnur Pharmaceuticals ( (SMNR) ) is now available.
On March 13, 2026, Semnur Pharmaceuticals announced the same-day retirement and resignation of Chief Executive Officer, President and director Jaisim Shah, whose departure was described as amicable and prompted a reduction of the board from six to five members, alongside a separation package including six months’ salary continuation and a short extension to exercise vested stock options. In connection with Shah’s exit, the board appointed long-time biotech executive and existing executive chair Henry Ji as Chief Executive Officer and President effective March 13, 2026, and named Chief Financial Officer Stephen Ma as Chief Operating Officer effective March 17, 2026, consolidating leadership under executives with deep ties to controlling shareholder Scilex and prior involvement in the 2025 SPAC business combination, transition services arrangements and related-party financing structures that continue to shape Semnur’s governance and operational framework.
More about Semnur Pharmaceuticals
Semnur Pharmaceuticals, Inc. is a pharmaceutical company that, following a 2025 business combination with SPAC Denali Capital Acquisition Corp., operates as a majority-owned subsidiary of Scilex Holding Company, which continues to beneficially own a significant stake. The company maintains ongoing operational links with Scilex through a transition services agreement under which Scilex provides administrative, financial, legal, IT and other support services, capped at $2 million per year for three years.
Average Trading Volume: 249
Technical Sentiment Signal: Sell
Current Market Cap: $1.84B
See more data about SMNR stock on TipRanks’ Stock Analysis page.